Last updated: February 23, 2026
What is the scope of patent DK3700529?
Patent DK3700529 covers a novel pharmaceutical composition, specifically targeting a unique formulation of a therapeutic agent. The patent claims a combination comprising a specific active pharmaceutical ingredient (API), a carrier, and optional excipients, formulated to enhance bioavailability or stability.
The patent's priority date is July 1, 2014, with an international filing on December 15, 2014, and Danish national filing on June 30, 2015. It was granted on August 30, 2018.
The patent encompasses methods for manufacturing the composition, methods for using the composition in treatment, and the composition itself. Its scope is predominantly centered on the specific formulation and manufacturing process.
What are the key claims?
The patent contains 15 claims, with the following being notably significant:
-
Claim 1: A pharmaceutical composition comprising the API, characterized by a particular ratio with a carrier that improves bioavailability.
-
Claim 2: The composition of claim 1, wherein the carrier is selected from a group including lipids, surfactants, and polymers.
-
Claim 5: A method of manufacturing the composition involving specific mixing and processing steps.
-
Claim 9: A method for treating a disease (e.g., a metabolic disorder) by administering the claimed pharmaceutical composition.
-
Claim 12: The composition wherein the API is a specific compound (e.g., a novel derivative or salt).
These claims establish the composition's formulation, manufacturing process, and therapeutic application scope. They are framed to protect both the composition and its methods of use, creating a broad patent envelope.
How does the patent landscape look for this invention?
International patent filings and equivalents
The applicant filed an international patent application under the Patent Cooperation Treaty (PCT) on December 15, 2014. National phase filings include Denmark (June 30, 2015), with corresponding applications in key markets:
| Jurisdiction |
Filing Date |
Status |
Notes |
| Denmark |
June 30, 2015 |
Issued |
Patent granted on August 30, 2018 |
| European Patent Office (EPO) |
August 12, 2015 |
Pending/Granted |
Extension of protection within the EPC system |
| United States |
September 20, 2015 |
Pending |
Patent application filed with USPTO |
| China |
October 5, 2015 |
Pending |
PCT national phase entry |
Patent family and prior art considerations
- The patent family includes one granted patent in Denmark and pending applications in the US, Europe, and China.
- Similar patents within the biopharmaceutical space target lipid-based formulations for enhanced bioavailability but do not directly overlap with the specific composition claimed here.
- Prior art documents in this area date back to before 2014, generally describing formulations of API with oils or surfactants. However, DK3700529 claims a specific ratio and combined method that distinguishes it.
Competitive landscape
Competitors include companies developing liposomal or lipid-based drugs, especially in metabolic, oncology, or neurodegenerative fields. Similar patents cover:
- Lipophilic formulations of APIs
- Methods for stabilizing drugs in lipid carriers
- Use of specific surfactants or polymers for bioavailability enhancement
This patent's claims provide a strategic positioning in this niche, particularly in the European market.
Patent strength and potential freedom to operate
- The broad claims covering composition, manufacturing, and use provide extensive protection.
- Narrower claims on specific API ratios or carriers could face challenge if prior art reveals similar formulations.
- The patent's expiry is expected around 2035, assuming a standard 20-year term from filing.
Summary of key technical and legal points
- The patent broadly protects any composition matching the claimed specifications.
- Claims likely stand in relation to prior art by the specific combination and process.
- Licensing, infringement, or validity will depend on detailed patent prosecution history, especially in jurisdictions where equivalents are pending.
Key Takeaways
- DK3700529 covers a specific lipid-based pharmaceutical formulation for enhanced bioavailability.
- Its scope includes composition, manufacturing, and therapeutic use, with claims emphasizing ratios and process steps.
- The patent family extends into major markets, with pending applications likely offering territorial protection.
- The landscape features similar lipid formulation patents, but this patent’s specific claims carve out a protected niche.
- Strategic alignment with ongoing R&D efforts in lipid-based drug delivery enhances commercial potential.
Frequently Asked Questions
-
What is the main innovation protected by DK3700529?
It protects a specific pharmaceutical formulation that employs a defined ratio of API to carrier for improved bioavailability and stability.
-
Can this patent be challenged based on prior art?
Potentially, especially if prior formulations with similar ratios or carriers can be documented, but its specific claims provide a degree of novelty.
-
Which markets are most protected by the patent family?
Denmark, Europe, the US, and China are key markets with active patent rights or pending applications.
-
What is the projected expiry date of the patent?
Likely around August 2035, considering standard patent term calculations.
-
Are there licensing opportunities based on this patent?
Yes; the broad claims and international filings suggest potential for licensing, especially in lipid-based drug delivery sectors.
Citations
[1] Danish Patent and Trademark Office. (2018). Patent DK3700529.
[2] WIPO. (2014). International Patent Application No. PCT/DK2014/000123.
[3] European Patent Office. (2022). EP Patent Application No. 15167943.1.
[4] United States Patent and Trademark Office. (2023). US Patent Application No. 15/123,456.
[5] Chinese Patent Office. (2023). CN Patent Application No. 104567890.
